(Q34112979)

31 July 2017

1 reference

title

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents (English)

1 reference

31 July 2017

F Ciardiello

1

1 reference

31 July 2017

1 January 2000

1 reference

31 July 2017

1 reference

31 July 2017

60 Suppl 1

1 reference

31 July 2017

25-32; discussion 41-2

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200060001-00003

31 July 2017

0 references

cites work

Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha

1 reference

12 December 2020

Epidermal growth factor receptor family and chemosensitization

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.

1 reference

12 December 2020

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

12 December 2020

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors

1 reference

12 December 2020

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice

1 reference

12 December 2020

Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts

1 reference

12 December 2020

Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines

1 reference

12 December 2020

Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents

1 reference

12 December 2020

Anticancer drug targets: growth factors and growth factor signaling

1 reference

12 December 2020

In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.

1 reference

12 December 2020

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma

1 reference

12 December 2020

4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.

1 reference

12 December 2020

Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model

1 reference

12 December 2020

Protein tyrosine kinase inhibitors as novel therapeutic agents

1 reference

12 December 2020

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor

1 reference

12 December 2020

Tyrosine kinase inhibitors in preclinical development

1 reference

12 December 2020

Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein

1 reference

12 December 2020

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

12 December 2020

Inhibitors of tyrosine kinase

1 reference

12 December 2020

Genistein exerts multiple suppressive effects on human breast carcinoma cells

1 reference

12 December 2020

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

1 reference

12 December 2020

Therapeutic application of anti-growth factor receptor antibodies

1 reference

12 December 2020

Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction

1 reference

12 December 2020

ZD1839 ('Iressa') as an anticancer agent

1 reference

12 December 2020

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms

1 reference

12 December 2020

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

12 December 2020

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner

1 reference

12 December 2020

Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: potent inhibitors of EGF receptor tyrosine kinase in vitro

1 reference

12 December 2020

Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

1 reference

12 December 2020

Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition

1 reference

12 December 2020

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

1 reference

12 December 2020

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

12 December 2020

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

1 reference

12 December 2020

Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain

1 reference

12 December 2020

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity

1 reference

12 December 2020

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

1 reference

12 December 2020

10.2165/00003495-200060001-00003

Identifiers

DOI

0 references

Dimensions Publication ID

0 references

1 reference

PubMed ID

11129169